Literature DB >> 26901495

Photoactivated inhibition of cathepsin K in a 3D tumor model.

Mackenzie K Herroon, Rajgopal Sharma, Erandi Rajagurubandara, Claudia Turro, Jeremy J Kodanko, Izabela Podgorski.   

Abstract

Collagenolytic activity of cathepsin K is important for many physiological and pathological processes including osteoclast-mediated bone degradation, macrophage function and fibroblast-mediated matrix remodeling. Here, we report application of a light-activated inhibitor for controlling activity of cathepsin K in a 3D functional imaging assay. Using prostate carcinoma cell line engineered to overexpress cathepsin K, we demonstrate the utility of the proteolytic assay in living tumor spheroids for the evaluation and quantification of the inhibitor effects on cathepsin K-mediated collagen I degradation. Importantly, we also show that utilizing the ruthenium-caged version of a potent nitrile cathepsin K inhibitor (4), cis-[Ru(bpy)2(4)2](BF4)2 (5), offers significant advantage in terms of effective concentration of the inhibitor and especially its light-activated control in the 3D assay. Our results suggest that light activation provides a suitable, attractive approach for spatial and temporal control of proteolytic activity, which remains a critical, unmet need in treatment of human diseases, especially cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26901495      PMCID: PMC5901740          DOI: 10.1515/hsz-2015-0274

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  63 in total

Review 1.  Development of nitrile-based peptidic inhibitors of cysteine cathepsins.

Authors:  Maxim Frizler; Marit Stirnberg; Mihiret Tekeste Sisay; Michael Gütschow
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 2.  Photoremovable protecting groups in chemistry and biology: reaction mechanisms and efficacy.

Authors:  Petr Klán; Tomáš Šolomek; Christian G Bochet; Aurélien Blanc; Richard Givens; Marina Rubina; Vladimir Popik; Alexey Kostikov; Jakob Wirz
Journal:  Chem Rev       Date:  2012-12-21       Impact factor: 60.622

3.  Miniaturized three-dimensional cancer model for drug evaluation.

Authors:  Carrie J Lovitt; Todd B Shelper; Vicky M Avery
Journal:  Assay Drug Dev Technol       Date:  2013-09       Impact factor: 1.738

4.  Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.

Authors:  Izabela Podgorski; Bruce E Linebaugh; Mansoureh Sameni; Christopher Jedeszko; Sunita Bhagat; Michael L Cher; Bonnie F Sloane
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

Review 5.  Cysteine cathepsins: multifunctional enzymes in cancer.

Authors:  Mona Mostafa Mohamed; Bonnie F Sloane
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

Review 6.  Cysteine cathepsins in human cancer.

Authors:  Christopher Jedeszko; Bonnie F Sloane
Journal:  Biol Chem       Date:  2004-11       Impact factor: 3.915

7.  Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.

Authors:  Izabela Podgorski; Bruce E Linebaugh; Jennifer E Koblinski; Deborah L Rudy; Mackenzie K Herroon; Mary B Olive; Bonnie F Sloane
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

8.  Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools.

Authors:  Sylvie Desmarais; Frédéric Massé; M David Percival
Journal:  Biol Chem       Date:  2009-09       Impact factor: 3.915

9.  Dipeptide nitrile inhibitors of cathepsin K.

Authors:  Eva Altmann; Reiner Aichholz; Claudia Betschart; Thomas Buhl; Jonathan Green; René Lattmann; Martin Missbach
Journal:  Bioorg Med Chem Lett       Date:  2006-02-09       Impact factor: 2.823

10.  Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins.

Authors:  Stefanie R Mullins; Mansoureth Sameni; Galia Blum; Matthew Bogyo; Bonnie F Sloane; Kamiar Moin
Journal:  Biol Chem       Date:  2012-12       Impact factor: 3.915

View more
  15 in total

1.  Effects of Methyl Substitution in Ruthenium Tris(2-pyridylmethyl)amine Photocaging Groups for Nitriles.

Authors:  Karan Arora; Jessica K White; Rajgopal Sharma; Shivnath Mazumder; Philip D Martin; H Bernhard Schlegel; Claudia Turro; Jeremy J Kodanko
Journal:  Inorg Chem       Date:  2016-06-29       Impact factor: 5.165

2.  Visible-to-NIR-Light Activated Release: From Small Molecules to Nanomaterials.

Authors:  Roy Weinstain; Tomáš Slanina; Dnyaneshwar Kand; Petr Klán
Journal:  Chem Rev       Date:  2020-10-30       Impact factor: 60.622

3.  Photochemical and Photobiological Activity of Ru(II) Homoleptic and Heteroleptic Complexes Containing Methylated Bipyridyl-type Ligands.

Authors:  Lars Kohler; Leona Nease; Pascal Vo; Jenna Garofolo; David K Heidary; Randolph P Thummel; Edith C Glazer
Journal:  Inorg Chem       Date:  2017-09-26       Impact factor: 5.165

4.  Ru(ii) polypyridyl complexes as photocages for bioactive compounds containing nitriles and aromatic heterocycles.

Authors:  Ao Li; Claudia Turro; Jeremy J Kodanko
Journal:  Chem Commun (Camb)       Date:  2018-02-01       Impact factor: 6.222

5.  Ru(II) Polypyridyl Complexes Derived from Tetradentate Ancillary Ligands for Effective Photocaging.

Authors:  Ao Li; Claudia Turro; Jeremy J Kodanko
Journal:  Acc Chem Res       Date:  2018-06-05       Impact factor: 22.384

6.  Caging the uncageable: using metal complex release for photochemical control over irreversible inhibition.

Authors:  Matthew Huisman; Jessica K White; Veronica G Lewalski; Izabela Podgorski; Claudia Turro; Jeremy J Kodanko
Journal:  Chem Commun (Camb)       Date:  2016-10-18       Impact factor: 6.222

7.  Light-responsive and Protic Ruthenium Compounds Bearing Bathophenanthroline and Dihydroxybipyridine Ligands Achieve Nanomolar Toxicity towards Breast Cancer Cells.

Authors:  Olaitan E Oladipupo; Spenser R Brown; Robert W Lamb; Jessica L Gray; Colin G Cameron; Alexa R DeRegnaucourt; Nicholas A Ward; James Fletcher Hall; Yifei Xu; Courtney M Petersen; Fengrui Qu; Ambar B Shrestha; Matthew K Thompson; Marco Bonizzoni; Charles Edwin Webster; Sherri A McFarland; Yonghyun Kim; Elizabeth T Papish
Journal:  Photochem Photobiol       Date:  2021-11-13       Impact factor: 3.421

8.  Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.

Authors:  Karan Arora; Mackenzie Herroon; Malik H Al-Afyouni; Nicholas P Toupin; Thomas N Rohrabaugh; Lauren M Loftus; Izabela Podgorski; Claudia Turro; Jeremy J Kodanko
Journal:  J Am Chem Soc       Date:  2018-10-22       Impact factor: 15.419

9.  New Ru(ii) complex for dual photochemotherapy: release of cathepsin K inhibitor and 1O2 production.

Authors:  Thomas N Rohrabaugh; Kelsey A Collins; Congcong Xue; Jessica K White; Jeremy J Kodanko; Claudia Turro
Journal:  Dalton Trans       Date:  2018-08-29       Impact factor: 4.390

10.  Singlet Oxygen Formation vs Photodissociation for Light-Responsive Protic Ruthenium Anticancer Compounds: The Oxygenated Substituent Determines Which Pathway Dominates.

Authors:  Fengrui Qu; Robert W Lamb; Colin G Cameron; Seungjo Park; Olaitan Oladipupo; Jessica L Gray; Yifei Xu; Houston D Cole; Marco Bonizzoni; Yonghyun Kim; Sherri A McFarland; Charles Edwin Webster; Elizabeth T Papish
Journal:  Inorg Chem       Date:  2021-02-03       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.